Strata Oncology scores $26 million for large-scale next-generation sequencing
The company plans to bring NGS to health systems lacking the ability to perform it internally.
Grail nets $300 million from Chinese investors in Series C round
Next-generation sequencing firm plans to present data on its gargantuan genomics study at ASCO next month.
presented by
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Another win for precision medicine: FDA approves companion diagnostic panel
After decades of research and theoretical debates, it seems precision oncology is finally falling into place, capped off with Thursday's approval of a companion diagnostic for multiple cancer therapies.
Thermo Fisher’s shopping spree continues with $5.2B acquisition of Patheon
The king of life science acquisitions has struck again. Thermo Fisher Scientific has announced plans to acquire Patheon, a Durham, North Carolina-based contract development and manufacturing organization with 9,000 employees worldwide.
Conserving biopsies: Thermo’s CDx panel nears approval
Thermo Fisher's universal companion diagnostic is nearing approval for NSCLC with the support of multiple pharma partners. The panel is designed to screen 47 genes with one small DNA input.
Former Affymetrix execs make offer for company that competes with Thermo Fisher’s
The new company, called Origin Technologies, are making this play about a week before Affymetrix shareholders plan to vote on the Thermo Fisher deal. The new bid will offer shareholders $16.10 per share in cash, up from Thermo Fisher's offer of $14 per share, as the New York Times points out.
